PPCB

Propanc Biopharma, Inc. Common Stock

NASDAQ: PPCB · HEALTHCARE · BIOTECHNOLOGY

$0.09

-12.65% today

Updated 2026-06-05

Market cap

$3.03M

P/E ratio

0.00

P/S ratio

—

EPS (TTM)

$570.50

Dividend yield

—

52W range

$1 – $270

Volume

3.1M

Market cap

$3.03M

P/E ratio

0.00

P/S ratio

—

EPS (TTM)

$570.50

Dividend yield

—

52W range

$1 – $270

Volume

3.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-17.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target

$1.52

+1579.56%

12-Month target

$354.35

+391446.96%

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.16x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -17.14 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-1.15M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-2.66M	$-2.66M	$-1.82M	$-58.92M	$-6.36M
EPS	—	—	—	—	$570.50
Free cash flow	$-1.44M	$-1.11M	$-935120.00	$-405168.00	$-1.15M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PPCB	$3.03M	26	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.01T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$567.28B	57	4.7	9.0	3.3	6.0	-73.18%	Buy
ABBV	$391.50B	63	4.0	8.0	4.0	5.0	-52.38%	Buy
UNH	$373.28B	54	5.3	5.5	4.0	5.5	-26.94%	Buy
NVS	$289.19B	49	3.3	9.0	3.3	4.5	-65.15%	Hold

Smart narrative

Propanc Biopharma, Inc. Common Stock trades at $0.09. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -17.14, it sits in the distress.

Frequently asked questions

What is Propanc Biopharma, Inc. Common Stock's stock price?

Propanc Biopharma, Inc. Common Stock (PPCB) trades at $0.09.

Is Propanc Biopharma, Inc. Common Stock overvalued?

Propanc Biopharma, Inc. Common Stock carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Propanc Biopharma, Inc. Common Stock (PPCB)?

The 12-month analyst consensus target is $1.52, about 1579.6% above the current $0.09. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Propanc Biopharma, Inc. Common Stock's Altman Z-Score is -17.14, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-127.00%

Beta3.40

50D MA$2.33

200D MA$19.47

Shares out0.00B

Float0.00B

Short ratio—

Avg volume3.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PPCB vs LLY →PPCB vs JNJ →PPCB vs ABBV →Stock screener →